Academic Partnerships AIkido leverages patented university-origin platforms and active collaborations with The University of Texas at Austin and University of Maryland Baltimore to access early-stage oncology and antiviral technologies, creating licensing and co-development opportunities with pharma partners.

Broad-spectrum Antivirals Developing a broad-spectrum antiviral platform with potential to inhibit replication of multiple viruses, including influenza and coronaviruses; sales opportunities include strategic licensing or co-development deals with large pharma for pandemic preparedness and cross-viral applications.

Oncology Focus Diverse small-molecule oncology portfolio targeting pancreatic and prostate cancers provides paths for partnered development, asset licensing, and milestone-driven deals with larger biopharma seeking niche, high-need oncology assets.

Funding Readiness Moderate revenue size and active financing history suggest appetite for partnership structures combining upfront payments, milestones, and potential co-investment from strategic partners to accelerate development.

Lean Growth Engine Small team footprint positions AIkido as a nimble partner for co-development and licensing deals, enabling efficient collaboration frameworks while leveraging external R&D resources and academic collaborations to expand the pipeline.